ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Dec 1, 2012
A Dual Focus on Valuation and Yield Is the Best Way to Combat Changes in Future Dividend Tax Rates
We think a dual focus on both valuation and high-yielders remains the best way to achieve portfolio income growth, while reducing the risk of permanent loss of capital from valuation missteps and exogenous events, namely potential changes in the dividend tax rate.
Oct 27, 2012
AstraZeneca Is Not Immune to Patent Cliff
AstraZeneca faced revenue and earnings pressure from the loss of exclusivity of Seroquel IR. Still, the firm boasts an impressive pipeline, and management reiterated its full-year earnings guidance.
Jul 2, 2012
Bristol-Myers Squibb and AstraZeneca Purchase Amylin
The two pharmaceutical companies will collaborate to commercialize the diabetes portfolio of Amylin. We think the deal is value neutral.
Jun 13, 2012
Johnson and Johnson’s Deal for Synthes Closes; Healthcare Spending Will Grow
We take a look at some recent developments in the healthcare industry.
Oct 21, 2011
Lilly's Third-Quarter Results Were Mixed; Patent Cliff Represents Major Risk
Lilly reported mixed third-quarter results, which revealed an earnings decline. The loss of US patent exclusivity on its top two drugs in the next couple years will be difficult to overcome. Investors may see a higher dividend yield on the stock, but only because of price declines.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.